Chronic Kidney Disease

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for micronutrient supplementation!

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for nutritional assessments!

A post hoc analysis from FIDELITY shows finerenone could significantly reduce eGFR slopes among patients at risk of worsening CKD due to a heart failure hospitalization.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

The consensus calls for the recognition of kidney disease as a major non-communicable disease driver of premature mortality by the World Health Organization.

Although the intervention did not reduce risk of CKD progression versus standard care, it addressed barriers to care and increased patients’ exposure to ACEi/ARBs.

Using the National Institutes of Health Toolbox Cognition Battery, results showed greater cognitive dysfunction across certain domains based on sex and CKD stage.

Findings call attention to the risk of complications in patients with CKD and UACR <30 mg/g, highlighting the dangers of elevated albuminuria even in the normoalbuminuric range.

Our March 2024 month in review highlights HCPLive’s top coverage of the latest news in nephrology, ranging from new CKD research and KDIGO guidelines to recent IgAN data.

A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

In this episode, Neuen talks about the FLOW trial, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.